Cronos Group (STU:7CI) Moat Score: 4/10 (As of Jul. 06, 2026)


STU:7CI Cronos Group Inc STU:7CI
85 GF Score
Price €2.47
GF Value €3.07
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Cronos Group Moat Score?

Cronos Group STU:7CI -1.04% 85 Moat Score is 4 as of Jul. 06, 2026. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.07 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,032 Drug Manufacturers companies, Cronos Group ranks better than 90.7% on this metric.

Cronos Group has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Cronos Group has Narrow Moat: Cronos has a strong brand in the cannabis industry and some proprietary technology. However, the market is highly competitive with regulatory challenges, limiting its ability to establish a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cronos Group might have Narrow Moat - Discernible but modest moat.

Cronos Group  (STU:7CI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cronos Group Moat Score Related Terms

STU:7CI vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cronos Group Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Cronos Group's Moat Score falls into.


STU:7CI
85GF Score
Cronos Group Inc STU:7CI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Cronos Group (STU:7CI) has a Moat Score of 4 as of Jul. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cronos Group ranks #96 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Cronos Group's Moat Score too high?
Cronos Group's current Moat Score is 4. Based on the distribution chart, Cronos Group ranks #96 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #96 out of 1032 companies for Moat Score. This places Cronos Group in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cronos Group's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.07, compared to a current price of €2.47 — trading 19.7% below its estimated fair value. The current Moat Score is 4. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current Moat Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cronos Group (STU:7CI) Overvalued in 2026?

Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued. The current stock price of €2.47 is trading 19.7% below its estimated GF Value™ of €3.07. GuruFocus considers Cronos Group to be Modestly Undervalued.

Key valuation signals for STU:7CI:

  • Moat Score: 4
  • GF Value™: €3.07 vs. price of €2.47 (19.7% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cronos Group Business Description

Other Exchanges CRON:USACRON:Canada
Address 4491 Concession Rd 12, Stayner, ON, CAN, L0M 1S0
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score

Get the complete analysis for STU:7CI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.47
Price
€3.07
GF Value